BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1028 related articles for article (PubMed ID: 8883281)

  • 1. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.
    Sartorio A; Cattaneo M; Bucciarelli P; Bottasso B; Porretti S; Epaminonda P; Faglia G; Arosio M
    Exp Clin Endocrinol Diabetes; 2000; 108(7):486-92. PubMed ID: 11083070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of growth hormone on fibrinolytic system in rat.
    Bubber P; Singh KP; Arora S; Bansal DD
    Indian J Exp Biol; 1998 May; 36(5):514-6. PubMed ID: 9717468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
    Sebestjen M; Zegura B; Guzic-Salobir B; Keber I
    Wien Klin Wochenschr; 2001 Feb; 113(3-4):113-8. PubMed ID: 11253736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
    Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
    Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
    Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG
    Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
    Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
    Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy.
    Rosenfalck AM; Fisker S; Hilsted J; Dinesen B; Vølund A; Jørgensen JO; Christiansen JS; Madsbad S
    Growth Horm IGF Res; 1999 Apr; 9(2):96-105. PubMed ID: 10373342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum homocysteine concentrations in children with growth hormone (GH) deficiency before and after 12 months GH replacement.
    Esposito V; Di Biase S; Lettiero T; Labella D; Simeone R; Salerno M
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):607-11. PubMed ID: 15521964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity.
    Primrose JN; Davies JA; Prentice CR; Hughes R; Johnston D
    Thromb Haemost; 1992 Oct; 68(4):396-9. PubMed ID: 1448769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
    Yuen KC; Frystyk J; White DK; Twickler TB; Koppeschaar HP; Harris PE; Fryklund L; Murgatroyd PR; Dunger DB
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):428-36. PubMed ID: 16181235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in the determinants of fibrinolytic activity.
    MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
    Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics.
    Dunstan DW; Mori TA; Puddey IB; Beilin LJ; Burke V; Morton AR; Stanton KG
    Thromb Haemost; 1999 Mar; 81(3):367-72. PubMed ID: 10102462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
    Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.